Sienna Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Selling, General & Admin	18.61	15.1	8	4.6
Research & Development	51.59	30.48	10.99	2.41
Operating Expenses	70.2	45.58	18.99	7.01
Operating Income	-70.2	-45.58	-18.99	-7.01
Interest Expense	-	-0.73	-	-0.48
Interest & Investment Income	-	0.49	-	-
Other Non Operating Income (Expenses)	3.03	-2.02	-0.47	-
EBT Excluding Unusual Items	-67.17	-47.85	-19.46	-7.49
Merger & Restructuring Charges	-	-	-1.7	-
Other Unusual Items	-6.3	-2.99	-	-3.8
Pretax Income	-73.47	-50.84	-21.16	-11.29
Income Tax Expense	-	-0.29	-	-
Net Income	-73.47	-50.55	-21.16	-11.29
Net Income to Common	-73.47	-50.55	-21.16	-11.29
Shares Outstanding (Basic)	20	10	2	2
Shares Outstanding (Diluted)	20	10	2	2
Shares Change (YoY)	110.07%	474.67%	-0.88%	-
EPS (Basic)	-3.59	-5.19	-12.49	-6.61
EPS (Diluted)	-3.59	-5.19	-12.49	-6.61
Free Cash Flow	-61.73	-41.29	-17.85	-10.07
Free Cash Flow Per Share	-3.02	-4.24	-10.54	-5.89
EBITDA	-70.04	-45.46	-18.92	-6.98
D&A For EBITDA	0.16	0.12	0.07	0.03
EBIT	-70.2	-45.58	-18.99	-7.01

Updated Nov 12, 2019. Source: S&P Global Market Intelligence. Standard template. Financial Sources.